T-Cell engager – Talk Bio

Cullinan Inks $700M Deal for BCMA Bispecific to Expand Autoimmune T-Cell Engager Portfolio

3 days ago talkbio0Tagged Autoimmune Diseases, biotech partnerships, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, bispecific, CD19xCD3, Clinical Development, CLN-978, Cullinan, Genrix Bio, Multiple Myeloma, T-Cell engager, velinotamig

Cullinan Therapeutics; Genrix Bio; BCMA bispecific; velinotamig; T-cell engager; autoimmune disease; CD19xCD3; CLN-978; multiple myeloma; clinical development; biotech partnerships

Candid Therapeutics Launches with $370 Million Funding, Aims to Revolutionize T Cell Engager Market for Autoimmune Diseases

9 months ago talkbio0Tagged Autoimmune Diseases, biotech, Candid, Drug Industry, Ken Song, T-Cell engager

Candid Therapeutics, T Cell Engager, Autoimmune Diseases, Biotech Funding, Ken Song, Pharmaceutical Industry

Gilead Sciences Strikes Deal with Merus for Trispecific Antibody Development

1 year ago talkbio0Tagged Cancer Therapeutic Procedure, Collaboration, Gilead Sciences, innovation, Merus NV, T-Cell engager, Trispecific antibodies

Gilead Sciences, Merus NV, Trispecific antibodies, T-Cell engager collaboration, Cancer therapy innovation